Member Info for Hikikomori

Yes Haddy,

MD Anderson are always the initial site for trials for companies who see investment from the focus fund.

Average investment is around the $5m mark, and since its inception 4 years ago around 10 companies have had funds allocated.

From Q1 next year, a much much larger funding round is opening, with around $250m available, and as investments are to remain at similar levels of around $5m, this funding round could benefit up to 50 companies.

Too much grog/throat massager, and then fallen overboard perhaps. Or maybe he’s skippering Stu’s Yacht somewhere in the Pacific Ocean.

That’s got absolutely nothing to do with CAR-T

What presentation, Drutor?

You will also see the free float is more like 30% when you do. Please stick to the facts

It’s not on AIM

Still considering an investment here, but I suspect it’s the below sentence that the market doesn’t like.

‘The Company is committed to securing the necessary funding to cover its share of the project over the next three years.’

Advice to Hemotruth,

Never argue with an idiot. They will drag you down to their level and beat you with experience.

The term ‘Do your own research’ has never been more true than when applying it to Hemo.

I’ll leave it at that.

Why should anyone trust a single word you say Mr I?

All of a sudden you were privy to the placing, but in the days before it was allegedly pulled you were screaming at anyone who would listen that there wasn’t going to be a placing.

In either scenario, you have shown yourself to be disingenuous and untrustworthy, in my opinion.

Apologies Hulver, didn’t notice the auto spell correct of your name in the last message.

Good summary Humber,

Also the additional developments with CDX, with Hemo having utilised Lonza’s bYlok bispecific pairing technology to develop a new and improved version of the CDX platform.

If this comes good for you Micky, I can just about picture you riding a horse bareback through the New Forest, shirtless with a can of Stella in hand

I’m sceptical about the whole placing rumours that have circulated since last night, but it’s good to see the SP climb today.

However, the rumours did make me recall a LinkedIn post from Vlad earlier in the year, where he quoted a line from Palantir’s Alex Karp.

"Almost nothing makes a human happier than taking the lines of cocaine away from these short sellers"

Monstermunch,

The otc share price is displayed as the last trade that went through, the 150 shares at 0.0423 cents. But I suspect you know that and are purposely trying to mislead others.

Porter,

Yes, the share price moved north today. That’s in no small part thanks to the guy you were calling a troll earlier, Lile, who stumped up for over 200k shares.

Definitely blastoid.

I actually invested in hemp once, but my investment went up in smoke.

It’s not strange at all John,

The shares will be issued to prevail in March, essentially for work which will be carried out from that point onwards for coordinating the paediatric trial.

They are basically taking shares as payment rather than cash. It’s not a difficult concept if you try and engage your brain.

Thanks Lile,

Good luck with your investment here.

I’ve no skin in this share, but was just looking at the board after reading an article on the company.

I have to say that Lile is absolutely correct, curiosity got the better of me so I checked.

See the below link and go to trade data.

It was 150 shares and the last trade of this share on otc prior to that was back in September. There’s no volume there at all.

https://www.otcmarkets.com/stock/GENFF/overview

Ssccss,

They can only issue above 20% if they issue a prospectus. There are strict regulations in the main market.